Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Patheon NV (PTHN) Share Price

News coverage about Patheon NV (NASDAQ:PTHN) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Patheon NV earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.7130628724235 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several analysts have commented on PTHN shares. Jefferies Group LLC reiterated a “hold” rating and issued a $35.00 price target on shares of Patheon NV in a research note on Friday, July 21st. BidaskClub cut shares of Patheon NV from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $33.60.

Shares of Patheon NV (NASDAQ:PTHN) opened at 34.98 on Friday. The firm has a 50-day moving average of $34.98 and a 200 day moving average of $34.98. The stock has a market cap of $5.08 billion and a PE ratio of 44.85. Patheon NV has a 52 week low of $24.45 and a 52 week high of $35.02.

TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at

Patheon NV Company Profile

Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.

Insider Buying and Selling by Quarter for Patheon NV (NASDAQ:PTHN)

Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with's FREE daily email newsletter.

Leave a Reply